LPAM
LFCR icon

Legion Partners Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Legion Partners Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.4M Hold
4,461,823
– – 57.75% 1
2026
Q1 		$16.6M Hold
4,461,823
– – 12.05% 3
2025
Q4 		$36.5M Hold
4,461,823
– – 21.25% 2
2025
Q3 		$32.8M Buy
4,461,823
+30,000
+0.7% +$227K 17.77% 4
2025
Q2 		$36M Hold
4,431,823
– – 21.63% 2
2025
Q1 		$31.2M Hold
4,431,823
– – 20.71% 2
2024
Q4 		$32.9M Buy
4,431,823
+1,463,414
+49% +$9.35M 19.21% 3
2024
Q3 		$14.6M Hold
2,968,409
– – 5.08% 9
2024
Q2 		$15.2M Buy
2,968,409
+18,182
+0.6% +$108K 4.7% 8
2024
Q1 		$15.7M Buy
2,950,227
+9,887
+0.3% +$70.7K 3.63% 11
2023
Q4 		$18.2M Hold
2,940,340
– – 4.74% 9
2023
Q3 		$22.2M Hold
2,940,340
– – 6.67% 7
2023
Q2 		$28.4M Hold
2,940,340
– – 8.31% 7
2023
Q1 		$11.1M Hold
2,940,340
– – 3.27% 11
2022
Q4 		$19.1M Hold
2,940,340
– – 5.84% 9
2022
Q3 		$26.1M Hold
2,940,340
– – 9.44% 7
2022
Q2 		$29.3M Hold
2,940,340
– – 7.61% 5
2022
Q1 		$34M Buy
2,940,340
+12,250
+0.4% +$136K 6.25% 9
2021
Q4 		$32.5M Hold
2,928,090
– – 6.08% 8
2021
Q3 		$27M Hold
2,928,090
– – 5.55% 9
2021
Q2 		$32.9M Hold
2,928,090
– – 6.62% 8
2021
Q1 		$31M Buy
2,928,090
+23,750
+0.8% +$267K 6.22% 7
2020
Q4 		$31.5M Hold
2,904,340
– – 8.2% 7
2020
Q3 		$28.2M Hold
2,904,340
– – 6.76% 6
2020
Q2 		$23.1M Buy
2,904,340
+522,847
+22% +$5.39M 6.47% 5
2020
Q1 		$20.7M Buy
2,381,493
+1,205,388
+102% +$12.5M 8.73% 5
2019
Q4 		$13.3M Buy
1,176,105
+566,245
+93% +$6.03M 3.45% 11
2019
Q3 		$6.63M Buy
+609,860
New +$6.64M 1.63% 11

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Legion Partners Asset Management's LFCR Position: Q2 2026 in Review

Legion Partners Asset Management held its Lifecore Biomedical (LFCR) position steady in Q2 2026 at 4,461,823 shares worth $23.4M. The position accounts for 57.75% of the portfolio, ranked #1.

Legion Partners Asset Management first reported a position in LFCR in Q3 2019 and has held it in 28 quarters since. The position peaked at $36.5M in Q4 2025. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Legion Partners Asset Management held 4,461,823 shares of Lifecore Biomedical worth $23.4M as of Q2 2026.
  • Legion Partners Asset Management left its Lifecore Biomedical share count unchanged in Q2 2026.
  • Lifecore Biomedical made up 57.75% of Legion Partners Asset Management's portfolio in Q2 2026, its #1 holding.
  • Legion Partners Asset Management first reported a position in Lifecore Biomedical in Q3 2019 and has held it in 28 quarters since.
  • Legion Partners Asset Management's Lifecore Biomedical position peaked at $36.5M in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Legion Partners Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.